Patents by Inventor Romas Kudirka

Romas Kudirka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunoconjugates Targeting PD-L1
    Publication number: 20220226491
    Abstract: The invention provides an immunoconjugate of formula (I) or (II). Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 21, 2022
    Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior University
    Inventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Justin Kenkel, Romas Kudirka, Arthur Lee, Brian Safina, Matthew Zhou, Edgar George Engleman
  • Immunoconjugates Targeting HER2
    Publication number: 20220226492
    Abstract: The invention provides an immunoconjugate of formula (I) or (II). Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds human epidermal growth factor receptor 2 (“HER2”) linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 21, 2022
    Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior University
    Inventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Romas Kudirka, Arthur Lee, Brian Safina, Matthew Zhou, Edgar George Engleman
  • ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF
    Publication number: 20220195066
    Abstract: The invention provides immunoconjugates of Formula I comprising an anti-CEA antibody linked by conjugation to one or more 8-Het-2-aminobenzazepine derivatives. The invention also provides 8-Het-2-aminobenzazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.
    Type: Application
    Filed: December 9, 2021
    Publication date: June 23, 2022
    Applicant: BOLT BIOTHERAPEUTICS, INC.
    Inventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Marcin Kowanetz, Romas Kudirka, Arthur Lee, William Mallet, Brian Safina, Matthew Zhou
  • Immunoconjugates Targeting CEA
    Publication number: 20220152215
    Abstract: The invention provides an immunoconjugate of formula (I) or (II) Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds carcinoembryonic antigen (“CEA”) linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.
    Type: Application
    Filed: March 13, 2020
    Publication date: May 19, 2022
    Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior University
    Inventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Marcin Kowanetz, Romas Kudirka, Arthur Lee, William Mallet, Brian Safina, Matthew Zhou, Edgar George Engleman
  • Macromolecule-Supported TLR Agonists
    Publication number: 20220143012
    Abstract: The invention provides a macromolecule-supported compound of formula (I) or (II). Macromolecule-supported compounds of the invention, comprising macromolecular support linked to one or more TLR agonists, are recognized by TLRs (e.g., TLR7 and/or TLR8) with high affinity providing utility in therapeutics, diagnostics, and chemical assays. The invention further provides compositions comprising and methods of treating cancer with the macromolecule-supported compounds.
    Type: Application
    Filed: March 13, 2020
    Publication date: May 12, 2022
    Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior University
    Inventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Justin Kenkel, Romas Kudirka, Arthur Lee, Brian Safina, Matthew Zhou, Edgar George Engleman
  • THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF
    Publication number: 20210128744
    Abstract: The invention provides immunoconjugates of Formula I comprising an antibody linked by conjugation to one or more thienoazepine derivatives. The invention also provides thienoazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.
    Type: Application
    Filed: October 23, 2020
    Publication date: May 6, 2021
    Applicant: BOLT BIOTHERAPEUTICS, INC.
    Inventors: Romas Kudirka, Brian Safina
  • AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF
    Publication number: 20200390899
    Abstract: The invention provides immunoconjugates of Formula I or III comprising an antibody linked by conjugation to one or more aminobenzazepine derivatives. The invention also provides aminobenzazepine derivative intermediate compositions of Formula II comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.
    Type: Application
    Filed: June 12, 2020
    Publication date: December 17, 2020
    Applicant: BOLT BIOTHERAPEUTICS, INC.
    Inventors: Shelley Erin Ackerman, Michael N. Alonso, Romas Kudirka, Arthur Lee, Brian Safina, Matthew Zhou
  • Nucleoside analog libraries
    Patent number: 7034147
    Abstract: The present invention provides combinatorial libraries of nucleoside analog compounds and methods of making the libraries. In addition, the present invention provides methods of assaying the libraries for agonists or antagonists of a broad array of targets of therapeutic importance.
    Type: Grant
    Filed: May 8, 2003
    Date of Patent: April 25, 2006
    Assignee: IRM LLC
    Inventors: Robert Epple, William Greenberg, Romas Kudirka
  • Nucleoside analog libraries
    Publication number: 20040006176
    Abstract: The present invention provides combinatorial libraries of nucleoside analog compounds and methods of making the libraries. In addition, the present invention provides methods of assaying the libraries for agonists or antagonists of a broad array of targets of therapeutic importance.
    Type: Application
    Filed: November 27, 2002
    Publication date: January 8, 2004
    Applicant: IRM LLC, a Delaware Limited Liability Company
    Inventors: Robert Epple, William Greenberg, Romas Kudirka
  • Nucleoside analog libraries
    Publication number: 20030225205
    Abstract: The present invention provides combinatorial libraries of nucleoside analog compounds and methods of making the libraries. In addition, the present invention provides methods of assaying the libraries for agonists or antagonists of a broad array of targets of therapeutic importance.
    Type: Application
    Filed: May 8, 2003
    Publication date: December 4, 2003
    Applicant: IRM LLC, a Delaware Limited Liability Company
    Inventors: Robert Epple, William Greenberg, Romas Kudirka